



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/33, C07K 14/03, C12N 5/00, C07K 16/08, G01N 33/50, C12Q 1/68, A61K 39/245	A1	(11) International Publication Number: WO 98/03657 (43) International Publication Date: 29 January 1998 (29.01.98)
(21) International Application Number: PCT/EP96/03199 (22) International Filing Date: 19 July 1996 (19.07.96) (71) Applicants (for all designated States except US): BEHRING DIAGNOSTICS GMBH [DE/DE]; Postfach 11 49, D-35001 Marburg (DE). NEW YORK UNIVERSITY [US/US]; 70 Washington Square, S., New York, NY 10012 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): FLECKENSTEIN, Bernhard [DE/DE]; Schlafhauser 228, D-91369 Wiesenthaue (DE). ALBRECHT, Jens-Christian [DE/DE]; Fichtenstrasse 61, D-90763 Fftrh (DE). NEIPEL, Frank [DE/DE]; Maria-Gebberstrasse 17, D-91080 Uttenreuth (DE). FRIEDMAN-KIEN, Alvin [US/US]; Apartment 2-3A, 1 Lexington Avenue, New York, NY 10010 (US). HUANG, Yao-Qi [US/US]; Apartment 7E, 333 East 30th Street, New York, NY 10016 (US). (74) Common Representative: BEHRING DIAGNOSTICS GMBH; Patente und Lizenzen, Postfach 11 49, D-35001 Marburg (DE).		(81) Designated States: US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: VIRAL INTERLEUKIN-6 (57) Abstract The present invention relates to viral interleukin-6 (v-IL-6), which can be obtained by recombinant expression of the DNA of human herpesvirus type 8 (HHV-8), and which may be used in diagnosis and treatment of human diseases such as kaposi sarcoma, Castleman's disease, multiple myeloma, kidney cell carcinoma, mesangial proliferative glomerulonephritis or B cell lymphoma.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Viral Interleukin-6

The present invention relates to viral interleukin-6 (v-IL-6), which can be obtained by recombinant expression of the DNA of human herpesvirus type 8 (HHV-8), and which may be used in diagnosis and treatment of human diseases such as kaposi sarcoma, Castleman's disease, multiple myeloma, kidney cell carcinoma, mesangial proliferative glomerulonephritis or B cell lymphoma.

Kaposi's sarcoma (KS), a multifocal proliferative lesion of uncertain pathogenesis, is highly prevalent among homosexual AIDS patients. Studies with biopsy materials and cultured cells have indicated an important role of growth factors and cellular cytokines, such as basic fibroblast growth factor, interleukin-1 β , platelet derived growth factor, interleukin-6 (IL-6), and oncostatin M for the proliferation of spindle cells in KS^{1,2}. Several groups found indication for the expression of interleukin-6 (IL-6) receptors in AIDS-KS cells³ and derived spindle cell lines⁴. As epidemiological evidence had suggested that an infectious agent other than HIV may also be involved in KS pathogenesis, it stirred considerable interest when Chang and colleagues⁵ found DNA sequences of a novel herpesvirus in AIDS-KS tissues. Meanwhile, DNA of this virus was consistently found in all epidemiological forms of KS. The new virus, termed human herpesvirus 8 (HHV-8), shows marked sequence homology to *herpesvirus (h.) saimiri*, the prototype of γ_2 -herpesviruses; thus HHV-8 appears to be the first human

member of γ_2 -herpesviruses (genus rhadinovirus). Cloning HHV-8 DNA from KS tissues and sequencing indicates a genome organization that is generally collinear to *h. saimiri*⁶.

In the course of these studies we surprisingly found, adjacent to a dihydrofolate reductase gene, an open reading frame (ORF) with the coding capacity for a 204 amino acid polypeptide with marked homology to mammalian IL-6 (P-value for homology searches with NCBI-BLAST: $P \leq 10^{-18}$; percent identity/similarity to human IL-6: 24.74%/ 46.91%; to murine: 24.23%/ 47.94%; to porcine: 25.97%/ 52.91%; to bovine: 24.60%/ 49.73%; all alignments were calculated with the GCG software "GAP").

The viral gene product (v-IL-6) has conserved all 4 cysteine residues that are known to be involved in IL-6 disulfide bridging, and it shows a characteristic signal peptide of 19 to 22 amino acids (fig. 1). The area involved in binding of human IL-6 to its receptor has been mapped to the middle of the protein by two groups^{7, 8, 9}. Ehlers et al. showed that amino acids 105 to 123 of the human IL-6, as shown in fig. 1 (GFNEEtCLVKlitGLLEFE), are involved in receptor binding. Most remarkably, this region is highly conserved in v-IL-6 (GFNEtCLkKLadGFFEFE). Identity and similarity of v-IL-6 to the receptor binding region of human IL-6 are 58% and 74%, respectively (fig. 1). This is almost identical with the degree of conservation that can be observed in this receptor binding area of human IL-6 to murine IL-6. As both human IL-6 and murine IL-6 are able to bind to the receptor of the other species (murine IL-6 and human IL-6, respectively), it is likely that v-IL-6 is also able to bind to the human and the murine IL-6 receptor.

Rhadinoviruses frequently acquire genes from their host cell¹⁰. This HHV-8 ORF however, is the first known example of a viral IL-6 structural homologue. Up to now all cell-homologous genes of rhadinoviruses that have been tested were functional; non-functional genes would most likely have been lost in viral evolution. Thus, the conservation of essential IL-6 features makes it highly suggestive that v-IL-6 is

functional in normal HHV-8 replication or persistence. Since models of paracrine growth stimulation of spindle cells by cytokines, including IL-6 and the related oncostatin M, have been proposed for KS pathogenesis, the finding of the v-IL-6 gene in HHV-8 lends support to the hypothesis that HHV-8 is causally related to this multifocal proliferation.

The present invention therefore relates to:

- a) Viral interleukin-6 (v-IL-6), which can be obtained by recombinant expression of the DNA of HHV-8.
- b) A polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2.
- c) A fragment of v-IL-6, having the capability of binding to an IL-6 receptor and comprising the amino acid sequence GFNEtsCLkKLadGFFEFE.
- d) A fragment as defined in b1, which essentially comprises the amino acid sequence GFNEtsCLkKLadGFFEFE.
- e) A fragment as defined in c or d, which binds to a human IL-6 receptor.
- f) A polypeptide having the amino acid sequence displayed in fig. 2.
- g) Mutants and variants of v-IL-6 or of the polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2, which mutants and variants are obtained by conventional amino acid substitutions or deletions, with the proviso that these mutants and variants are functionally equivalent to v-IL-6.

- 4 -

- h) Fragments of v-IL-6, or of the polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2, characterized in that they are able to competitively inhibit the biological activity of IL-6 in a suitable assay system.
- i) An isolated nucleic acid coding for v-IL-6 or the polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2. A preferred embodiment is the nucleic acid having the nucleotide sequence of fig.2. Furthermore, an isolated nucleic acid, hybridizing to the abovementioned nucleic acids under stringent conditions and encoding functionally active v-IL-6 shall be comprised.
- k) Monoclonal or polyclonal antibodies directed against v-IL-6 or the polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2.
- l) Testkit for the detection of v-IL-6 in a sample, comprising one or more of the above monoclonal or polyclonal antibodies.
- m) Testkit for the detection of antibodies against v-IL-6 comprising v-IL-6 and/or the polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2, and/or mutants and variants of v-IL-6 or the polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2 and/or fragments of v-IL-6 or the polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2.
- n) Testkit for the detection of v-IL-6 DNA or RNA, comprising a nucleic acid which codes for v-IL-6, or which hybridizes to the aforementioned nucleic acid and encodes functionally active v-IL-6.

- o) A medicament comprising as an active ingredient a monoclonal antibody or polyclonal antibodies directed against v-IL-6, or a polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2, or mutants, variants or fragments of v-IL-6 or the aforementioned polypeptide. In another embodiment, the medicament may comprise as an active ingredient a nucleic acid encoding v-IL-6.
- p) A cell culture growth medium, comprising as an active ingredient v-IL-6 or the polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2, or mutants, variants or fragments of v-IL-6 or the aforementioned polypeptide.
- q) A process of manufacturing v-IL-6 or the polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2, or mutants and variants, or fragments of v-IL-6 or the aforementioned polypeptide.
- r) A process of manufacturing a medicament, wherein the active ingredient is combined with suitable excipients and/or other auxiliary compounds according to common knowledge of those skilled in the art.
- s) A process of manufacturing a medicament comprising as an active ingredient monoclonal or polyclonal antibodies directed against v-IL-6, or a polypeptide comprising v-IL-6, or mutants, variants or fragments of v-IL-6, or a nucleic acid encoding v-IL-6 for the treatment of kaposi sarcoma, Castleman's disease, multiple myeloma, kidney cell carcinoma, mesangial proliferative glomerulonephritis or B cell lymphoma.

- 6 -

- t) A process of diagnosing an HHV-8 infection comprising the in vitro detection of v-IL-6 antigen, v-IL-6 DNA, v-IL-6 RNA or antibodies against v-IL-6.
- u) A process of diagnosing the HHV-8 associated disorders kaposi sarcoma, Castleman's disease or body cavity based lymphomas (BCBL) through the diagnosis of an HHV-8 infection as described above.
- v) A process of growing cells in culture, characterized in that v-IL-6 or the polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2, or mutants and variants, or fragments of v-IL-6 or the aforementioned polypeptide, or mixtures of these compounds are contained in the growth medium. In a preferred process these cells are B-lymphocytes, hybridomas, hemopoietic cells or endothelial cells.

The sequence shown in fig.2 was generated by first subcloning shotgun fragments of lambda clone G16 into commercially available plasmid pBS KS- (Stratagene, San Diego, califormia). Resulting plasmids were purified using a commercially available kit (Qiagen, Hilden, Germany) and sequenced on an automated sequencing system (A377, Applied Biosystems GmbH, Weiterstadt, Germany) using the recommendations of the manufacturer. The sequence was determined on both strands, using standard primers for shotgun clones, and gene specific primers for further analysis. In addition to showing the coding sequence of the interleukin-6 homologue of human herpesvirus 8, the deduced amino acid sequence, in one and three letter code, is shown in the sequence listing below.

The present invention is further described in the claims.

Bibliography:

1. Miles, S. A. et al.: *Science*, 255, 1432-1434 (1992).
2. Stürzl, M. et al.: *Oncogene* 10, 2007-2016 (1995).
3. Miles, S. A. et al.: *Proc. Natl. Acad. Sci. U. S. A.* 87, 4068-4072 (1990).
4. Masood, R. et al.: *AIDS Res. Hum. Retroviruses* 10, 969-975 (1994).
5. Chang, Y. et al.: *Science*. 266, 1865-1869 (1994).
6. Moore, P. S. et al.: *J. Virol.* 70, 549-558 (1996).
7. Hammacher, A. et al.: *Protein Sci.* 3, 2280-2293 (1994).
8. Ehlers, M. et al.: *J. Immunol.* 153, 1744-1753 (1994).
9. Ehlers, M. et al.: *Ann. N.Y. Acad. Sci.* 762, 400-402 (1995).
10. Albrecht, J. C. et al.: *J. Virol.* 66, 5047-5058 (1992).

Legends:**Figure 1:**

Alignment of the sequences of the predicted protein precursor of the HHV-8 IL-6 gene with human and mouse IL-6. Amino acids identical in all three proteins are indicated by an asterisk, cysteine residues involved in disulfide bridging are marked with an arrowhead. Upper case letters symbolize amino acids conserved according to the criteria defined by M. Dayhoff.

Figure 2:

Nucleic acid sequence encoding v-IL-6 and corresponding amino acid sequence.

Claims:

1. Viral interleukin-6 (v-IL-6), which can be obtained by recombinant expression of the DNA of HHV-8.
2. A polypeptide, which can be obtained by recombinant expression of the DNA of HHV-8, and which comprises the amino acid sequence displayed in fig. 2.
3. A polypeptide having the amino acid sequence displayed in fig. 2.
4. A fragment of v-IL-6, having the capability of binding to an IL-6 receptor and comprising the amino acid sequence GFNEtsCLkKLadGFFEFE.
5. A fragment as claimed in claim 4, which essentially comprises the amino acid sequence GFNEtsCLkKLadGFFEFE.
6. A fragment as claimed in claim 4 or 5, which binds to a human IL-6 receptor.
7. Mutants and variants of v-IL-6 as claimed in claim 1, or of the polypeptide as claimed in claim 2, which mutants and variants are obtained by conventional amino acid substitutions or deletions, with the proviso that these mutants and variants are functionally equivalent to v-IL-6.
8. Fragments of the v-IL-6 as claimed in claim 1, or the polypeptide as claimed in claim 2 or 3, characterized in that they are able to competitively inhibit the biological activity of IL-6 in a suitable assay system.
9. An isolated nucleic acid coding for v-IL-6 as claimed in claim 1.
10. An isolated nucleic acid coding for the polypeptide as claimed in claim 2.

11. An isolated nucleic acid having the nucleotide sequence displayed in fig. 2.
12. An isolated nucleic acid, hybridizing under stringent conditions to the nucleic acid as claimed in one or more of the claims 9 to 11, encoding functional v-IL-6.
13. Monoclonal or polyclonal antibodies directed against v-IL-6 as claimed in claim 1, or the polypeptide as claimed in claim 2 and/or 3.
14. Testkit for the detection of v-IL-6 in a sample, comprising an antibody as claimed in claim 16.
15. Testkit for the detection of antibodies against v-IL-6, comprising v-IL-6 as claimed in claim 1 and/or the polypeptide as claimed in claim 2 or 3 or both, claims 2 and 3, and/or mutants and variants of v-IL-6 as claimed in claim 7, and/or fragments of v-IL-6 as claimed in claim 4-6 or 8.
16. Testkit for the detection of v-IL-6 DNA or RNA, comprising a nucleic acid as claimed in one or more of the claims 9 to 12.
17. A medicament comprising as an active ingredient the antibody as claimed in claim 13.
18. A medicament comprising as an active ingredient v-IL-6 as claimed in claim 1 and/or the polypeptide as claimed in claim 2 or 3, and/or mutants and variants of v-IL-6 as claimed in claim 7, and/or fragments of v-IL-6 as claimed in claim 4-6 or 8.
19. A medicament comprising as an active ingredient the nucleic acid as claimed in one or more of claims 9 to 12.
20. A cell culture growth medium, comprising as an additional active ingredient v-IL-6 as claimed in claim 1, or the polypeptide as claimed in claim 2 or 3, or mutants and variants as claimed in claim 7, or fragments as claimed in claim 8, or mixtures of these substances.

21. A process of manufacturing v-IL-6 as claimed in claim 1, or the polypeptide as claimed in claim 2 or 3, or mutants and variants as claimed in claim 7, or fragments as claimed in claim 4-6 or 8.
22. A process of manufacturing a medicament, wherein v-IL-6 as claimed in claim 1, or the polypeptide as claimed in claim 2 or 3, or mutants and variants as claimed in claim 7, or fragments as claimed in claim 8 are combined with suitable excipients and/or other auxiliary compounds.
23. A process of manufacturing a medicament comprising as an active ingredient monoclonal or polyclonal antibodies directed against v-IL-6, or a polypeptide comprising v-IL-6, or mutants, variants or fragments of v-IL-6, or a nucleic acid encoding v-IL-6 for the treatment of kaposi sarcoma, Castleman's disease, multiple myeloma, kidney cell carcinoma, mesangial proliferative glomerulonephritis or B cell lymphoma.
24. An process of diagnosing an HHV-8 infection comprising the in vitro detection of v-IL-6 antigen, v-IL-6 DNA, v-IL-6 RNA or antibodies against v-IL-6.
25. A process of diagnosing the HHV-8 associated disorders kaposi sarcoma, Castleman's disease or body cavity based lymphomas (BCBL) through the diagnosis of an HHV-8 infection as claimed in claim 24.
26. A process of growing cells in culture, characterized in that v-IL-6 as claimed in claim 1, or the polypeptide as claimed in claim 2 or 3, or mutants and variants as claimed in claim 7, or fragments as claimed in claim 4-6 or 8, or mixtures of these compounds are contained in the growth medium.
27. The process as claimed in claim 26, wherein the cells are B-lymphocytes, hybridomas, hemopoetic cells or endothelial cells.

1/4

Fig. 1:

	1	56
Il6 human	MnsFStsaFgPVAfSLGLLLLVlpaAFPapvppgeDskDvaaPhRQpLTsSErIDkq	
Il6 mouse	MkFLSaRdFhPVAf.LGLMLVttTAFptsqvrRGDFtEdttPnRpVyTtSQ.VGgl	
Il6 hhv8	McWFKlWsL....LLVGsLLVsgT.....RGkLpDapefeKDLLi.....qr	
Consensus	* * *	
	57	112
Il6 human	IrYILdgIsaLRKEtCNKsnMCeSskeALAENNLnLPkMaEkDGCFQsGFNEEtCL	
Il6 mouse	IthVLWeIvEMRKELCNgnSdCmnndDALAENNLKLPeIqrndGCYQtGYNQeiCL	
Il6 hhv8	LnWMLWvIdEcfrDLCyRtGICkGilePaAifhLKLPaInDtDhCgliGFNEtsCL	
Consensus	* * * * * * * * *	
	113	168
Il6 human	VKIitGLLEFEVYLEYLqNrF.EsSeEqARaVQMSTKvLIQFLQkkaKNLdaIttP	
Il6 mouse	LKIssGLLEYhsYLEYMkNnLkDnkkDkARVLQrdTeTLIHIFnQEVKDLhKivlP	
Il6 hhv8	kKLadGFFEFELFkFLtteF.GkSvinvdVMELlTKTLgwdIQEELnkLtKthys	
Consensus	* * * * *	
	169	223
Il6 human	dPttNASLLtKLQAQnQWLqdmTtHLILRSFkEFLqssLRaLRQM.....	
Il6 mouse	tPisNAIltdKLESQKEWLrtkTiQFILKSLEEFkvtLRstRQt.....	
Il6 hhv8	pPkfDrGLLGRlQGlKyWVRhfasfYVLsaMEkFagqaVRvLdsIpdvtpdvhdK	
Consensus	* * * * *	

Fig. 2:

SEQUENCE LISTING

1. Sequence characteristics:
 - 1.1. Length: 612 base pairs
 - 1.2. Type: Nucleic Acid
 - 1.3. Strandedness: Double stranded
 - 1.4. Topology: Linear
2. Molecule type: Genomic DNA
3. Description: Human herpesvirus 8 interleukin-6 gene
4. Hypothetical: No
5. Anti-sense: No
6. Original source: Kaposi Sarkoma from HIV positive donor
7. Organism: Human herpesvirus 8

3/4

1	ATG	TGC	TGG	TTC	AAG	TTG	TGG	TCT	CTC	TTG	CTG	GTC	GGT	TCA	CTG
1	M	C	W	F	K	L	W	S	L	L	L	V	G	S	L
1	Met	Cys	Trp	Phe	Lys	Leu	Trp	Ser	Leu	Leu	Leu	Val	Gly	Ser	Leu
46	CTG	GTA	TCT	GGA	ACG	CGG	GGC	AAG	TTG	CCG	GAC	GCC	CCC	GAG	TTT
16	L	V	S	G	T	R	G	K	L	P	D	A	P	E	F
16	Leu	Val	Ser	Gly	Thr	Arg	Gly	Lys	Leu	Pro	Asp	Ala	Pro	Glu	Phe
91	GAA	AAG	GAT	CTT	CTC	ATT	CAG	AGA	CTC	AAT	TGG	ATG	CTA	TGG	GTG
31	E	K	D	L	L	I	Q	R	L	N	W	M	L	W	V
31	Glu	Lys	Asp	Leu	Leu	Ile	Gln	Arg	Leu	Asn	Trp	Met	Leu	Trp	Val
136	ATC	GAT	GAA	TGC	TTC	CGC	GAC	CTC	TGT	TAC	CGT	ACC	GGC	ATC	TGC
46	I	D	E	C	F	R	D	L	C	Y	R	T	G	I	C
46	Ile	Asp	Glu	Cys	Phe	Arg	Asp	Leu	Cys	Tyr	Arg	Thr	Gly	Ile	Cys
181	AAG	GGT	ATT	CTA	GAG	CCC	GCT	GCT	ATT	TTT	CAT	CTG	AAA	CTA	CCA
61	K	G	I	L	E	P	A	A	I	F	H	L	K	L	P
61	Lys	Gly	Ile	Leu	Glu	Pro	Ala	Ala	Ile	Phe	His	Leu	Lys	Leu	Pro
226	GCC	ATC	AAC	GAT	ACT	GAT	CAC	TGC	GGG	TTA	ATA	GGA	TTT	AAT	GAG
76	A	I	N	D	T	D	H	C	G	L	I	G	F	N	E
76	Ala	Ile	Asn	Asp	Thr	Asp	His	Cys	Gly	Leu	Ile	Gly	Phe	Asn	Glu
271	ACT	AGC	TGC	CTT	AAA	AAG	CTC	GCC	GAT	GGC	TTT	TTT	GAA	TTC	GAG
91	T	S	C	L	K	K	L	A	D	G	F	F	E	F	E
91	Thr	Ser	Cys	Leu	Lys	Lys	Leu	Ala	Asp	Gly	Phe	Phe	Glu	Phe	Glu
316	GTG	TTG	TTT	AAG	TTT	TTA	ACG	ACG	GAG	TTT	GGA	AAA	TCA	GTG	ATA
106	V	L	F	K	F	L	T	T	E	F	G	K	S	V	I
106	Val	Leu	Phe	Lys	Phe	Leu	Thr	Thr	Glu	Phe	Gly	Lys	Ser	Val	Ile
361	AAC	GTG	GAC	GTC	ATG	GAG	CTT	CTG	ACG	AAG	ACC	TTA	GGA	TGG	GAC
121	N	V	D	V	M	E	L	L	T	K	T	L	G	W	D
121	Asn	Val	Asp	Val	Met	Glu	Leu	Leu	Thr	Lys	Thr	Leu	Gly	Trp	Asp
406	ATA	CAG	GAA	GAG	CTC	AAT	AAG	CTG	ACT	AAG	ACG	CAC	TAC	AGT	CCA
136	I	Q	E	E	L	N	K	L	T	K	T	H	Y	S	P
136	Ile	Gln	Glu	Glu	Leu	Asn	Lys	Leu	Thr	Lys	Thr	His	Tyr	Ser	Pro
451	CCC	AAA	TTT	GAC	CGC	GGT	CTA	TTA	GGG	AGG	CTT	CAG	GGA	CTT	AAG
151	P	K	F	D	R	G	L	L	G	R	L	Q	G	L	K
151	Pro	Lys	Phe	Asp	Arg	Gly	Leu	Leu	Gly	Arg	Leu	Gln	Gly	Leu	Lys
496	TAT	TGG	GTG	AGA	CAC	TTT	GCT	TCG	TTT	TAT	GTT	CTG	AGT	GCA	ATG
166	Y	W	V	R	H	F	A	S	F	Y	V	L	S	A	M
166	Tyr	Trp	Val	Arg	His	Phe	Ala	Ser	Phe	Tyr	Val	Leu	Ser	Ala	Met

4/4

541 GAA AAG TTT GCA GGT CAA GCG GTG CGT GTT TTG GAC TCT ATC CCA
181 E K F A G Q A V R V L D S I P
181 Glu Lys Phe Ala Gly Gln Ala Val Arg Val Leu Asp Ser Ile Pro

586 GAC GTG ACT CCT GAC GTC CAC GAT AAG
196 D V T P D V H D K
196 Asp Val Thr Pro Asp Val His Asp Lys

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 96/03199

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/33 C07K14/03 C12N5/00 C07K16/08 G01N33/50
C12Q1/68 A61K39/245

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N G01N C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	J VIROL, JAN 1997, 71 (1) P839-42, UNITED STATES, XP000645323 NEIPEL F ET AL: "Human herpesvirus 8 encodes a homolog of interleukin-6." see the whole document ---	1-3,6-27
P,X	PROC NATL ACAD SCI U S A, DEC 10 1996, 93 (25) P14862-7, UNITED STATES, XP000645332 RUSSO JJ ET AL: "Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8)." see figure 1; table 1 --- -/-	1-3,6-12

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

20 March 1997

Date of mailing of the international search report

01.04.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Espen, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 96/03199

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	SCIENCE, DEC 6 1996, 274 (5293) P1739-44, UNITED STATES, XP002027822 MOORE PS ET AL: "Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV." see figure 1B ---	1-3,6-12
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, June 1996, WASHINGTON US, pages 6641-6646, XP002027823 ZHONG W ET AL.: "Restricted expression of Kaposi sarcoma associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma" -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 96/03199

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 4,5
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Claims not searched. The amino acid sequence given in these claims lacks clarity, since the single letter code used does not comply with the official code generally used.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/33, C07K 14/03, C12N 5/00, C07K 16/08, G01N 33/50, C12Q 1/68, A61K 39/245	A1	(11) International Publication Number: WO 98/03657 (43) International Publication Date: 29 January 1998 (29.01.98)
(21) International Application Number: PCT/EP96/03199 (22) International Filing Date: 19 July 1996 (19.07.96) (71) Applicants (for all designated States except US): BEHRING DIAGNOSTICS GMBH [DE/DE]; Postfach 11 49, D-35001 Marburg (DE). NEW YORK UNIVERSITY [US/US]; 70 Washington Square, S., New York, NY 10012 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): FLECKENSTEIN, Bernhard [DE/DE]; Schlafhausen 228, D-91369 Wiesentha (DE). ALBRECHT, Jens-Christian [DE/DE]; Fichtenstrasse 61, D-90763 Fürth (DE). NEIPEL, Frank [DE/DE]; Maria-Gebberstrasse 17, D-91080 Uttenreuth (DE). FRIEDMAN-KIEN, Alvin [US/US]; Apartment 2-3A, 1 Lexington Avenue, New York, NY 10010 (US). HUANG, Yao-Qi [US/US]; Apartment 7E, 333 East 30th Street, New York, NY 10016 (US). (74) Common Representative: BEHRING DIAGNOSTICS GMBH; Patente und Lizenzen, Postfach 11 49, D-35001 Marburg (DE).		(81) Designated States: US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: VIRAL INTERLEUKIN-6 (57) Abstract The present invention relates to viral interleukin-6 (v-IL-6), which can be obtained by recombinant expression of the DNA of human herpesvirus type 8 (HHV-8), and which may be used in diagnosis and treatment of human diseases such as kaposi sarcoma, Castleman's disease, multiple myeloma, kidney cell carcinoma, mesangial proliferative glomerulonephritis or B cell lymphoma.		

09/230048 2

PATENT COOPERATION TREATY

PCT



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

5650

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 96927558.5	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (PCT/IPEA/416)	
International application No. PCT/EP96/03199	International filing date (day/month/year) 19/07/1996	Priority date (day/month/year) 19/07/1996
International Patent Classification (IPC) or national classification and IPC C12N15/33		
Applicant DADE BEHRING MARBURG GMBH		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 5 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 25/09/1997	Date of completion of this report 25.10.98
Name and mailing address of the IPEA/  European Patent Office D-80298 Munich Tel. (+49-89) 2399-0. Tx: 523656 epmu d Fax: (+49-89) 2399-4465	Authorized officer Stolz. B Telephone No. (+49-89) 2399-8416 

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP96/03199

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-7 as originally filed

Claims, No.:

1-27 as originally filed

Drawings, sheets:

12-15 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious). or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 4-6.

because:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP96/03199

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 4-6.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-3, 9-11, 15, 16, 18-27
	No:	Claims	7, 8, 12-14, 17
Inventive step (IS)	Yes:	Claims	1-3, 9-11, 15, 16, 18-27
	No:	Claims	7, 8, 12-12, 17
Industrial applicability (IA)	Yes:	Claims	1-27
	No:	Claims	

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

1. Reasoned statement

- 1.1. The application discloses a DNA and amino acid sequence, termed v-IL6, obtainable from HHV-8. Based on the pathological consequences of HHV-8 infection and partial sequence homology with human IL6, the molecule is claimed to be functionally homologous to human IL6. Basically claimed are v-IL6, variants and fragments thereof, DNAs coding for these proteins, antibodies against such proteins, methods of manufacturing v-IL6 and various uses of the claimed DNAs and proteins.
- 1.2. v-IL6, as defined by the sequence of Fig. 2 appears to be novel and inventive, as the existence of a functional homolog of human IL6 with this particular structure was neither disclosed nor made obvious in the available prior art.

The application does not provide any further information with regard to additional and possibly new functions of v-IL6. Therefore, as mentioned above and in the description of the present application, the new molecule is considered to be functionally homologous or equivalent to human IL6. The functional limitations of claims 7, 8 and 12 appear thus to refer to a function homologous to that of human IL6, or in other words to a known function. Given this functional homology, fragments, variants and mutants of v-IL6 would have to differ structurally in a new and non-obvious way from previously known fragments and variants of IL6 in order to meet the requirements of Art. 33(2) and (3) PCT. However, claims 7, 8 and 12 do not specify defined sequences of such nature but refer to fragments, variants and mutants in general terms. Numerous active fragments of human IL6 have been described. They are by definition functionally equivalent to v-IL6 and given the considerable degree of sequence homology fall certainly under the definition of mutants and variants of v-IL6. Along the same line of arguments, fragments and variants of human or murine IL6 might fall under the definition of claim 8. IL6 itself might fall under the definition of claim 12. Claims 7, 8 and 12 are therefore considered to lack novelty.

- 1.3. Claim 13 is directed to any antibody recognizing epitopes on v-IL6. Since there is considerable sequence homology with the receptor binding site of human IL6 and antibodies against human IL6 are known, it is highly likely that some known anti-

human IL6 antibodies fall under the definition of claim 13. Claims 13, 14 and 17 are therefore considered to lack novelty.

- 1.4. Consequently, only those of the remaining claims which refer to the use of the new and inventive sequences of Fig. 2 meet the requirements of articles 33(2) and 33(3) PCT.

2. Certain observations

- 2.1. Claims 1 and 9 do not meet the requirements of Art. 6 PCT alone and in combination with Rule 6.3(a) PCT. The claims lack technical features, i.e. a reference to a DNA or amino acid sequence. As it stands, the term v-IL6 is arbitrary, based on partial sequence homology with IL6. It is not clear if it is also meant to include functional limitations. The claims need reference to structural features in order to meet the requirements of Rule 6.3(a). The term HHV-8 should be spelled out in claim 1.
- 2.2. Claims 23 to 25 do also not meet the requirements of Art. 6 PCT and Rule 6.3(a) PCT. They refer to the use of v-IL6, and fragments and variants thereof in different processes. v-IL6, fragments and variants thereof are arbitrary terms without any functional or structural limitations. The scope of the claims can thus not be determined unambiguously.
- 2.3. Claims 21 and 23 do not meet the requirements of Art. 6 PCT. Both claims cover processes, but do not appear to specify any process features.
- 2.4. The claims contain a number of unclear terms (Art. 6 PCT), eventually rendering their scope unclear. They are: "essentially" in claim 5, "functionally equivalent" in claim 7, and a "suitable assay system" in claim 8.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 1996/B006-Ma	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/EP 96/03199	International filing date (day/month/year) 19/07/1996	(Earliest) Priority Date (day/month/year)
Applicant BEHRINGWERKE AKTIENGESELLSCHAFT et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☒ Certain claims were found unsearchable (see Box I).

2. ☐ Unity of invention is lacking (see Box II).

3. ☒ The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing

☐ filed with the international application.

☒ furnished by the applicant separately from the international application,

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ Transcribed by this Authority

4. With regard to the title, ☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:

Figure No. _____ ☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: **4, 5**
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Claims not searched. The amino acid sequence given in these claims lacks clarity, since the single letter code used does not comply with the official code generally used.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/EP 96/03199

A. CLASSIFICATION OF SUBJECT MATTER

 IPC 6 C12N15/33 C07K14/03 C12N5/00 C07K16/08 G01N33/50
 C12Q1/68 A61K39/245

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N G01N C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	J VIROL, JAN 1997, 71 (1) P839-42, UNITED STATES, XP000645323 NEIPEL F ET AL: "Human herpesvirus 8 encodes a homolog of interleukin-6." see the whole document ---	1-3,6-27
P,X	PROC NATL ACAD SCI U S A, DEC 10 1996, 93 (25) P14862-7, UNITED STATES, XP000645332 RUSSO JJ ET AL: "Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8)." see figure 1; table 1 --- -/--	1-3,6-12

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 March 1997

Date of mailing of the international search report

01.04.97

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

Espen, J

INTERNATIONAL SEARCH REPORT

Intern. Application No.
PCT/EP 96/03199

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	SCIENCE, DEC 6 1996, 274 (5293) P1739-44, UNITED STATES, XP002027822 MOORE PS ET AL: "Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV." see figure 1B ---	1-3,6-12
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, June 1996, WASHINGTON US, pages 6641-6646, XP002027823 ZHONG W ET AL.: "Restricted expression of Kaposi sarcoma associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma" -----	

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

DADE BEHRING MARBURG GMBH
Patente und Lizenzen
Postfach 11 49
D-35001 Marburg
ALLEMAGNE

Date of mailing (day/month/year) 28 April 1998 (28.04.98)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 96927558.5	
International application No. PCT/EP96/03199	International filing date (day/month/year) 19 July 1996 (19.07.96)

1. The following indications appeared on record concerning:		
<input checked="" type="checkbox"/> the applicant	<input type="checkbox"/> the inventor	<input type="checkbox"/> the agent
<input type="checkbox"/> the common representative		
Name and Address BEHRING DIAGNOSTICS GMBH Postfach 11 49 D-35001 Marburg Germany	State of Nationality DE	State of Residence DE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
<input type="checkbox"/> the person	<input checked="" type="checkbox"/> the name	<input type="checkbox"/> the address
<input type="checkbox"/> the nationality		
<input type="checkbox"/> the residence		
Name and Address DADE BEHRING MARBURG GMBH Postfach 11 49 D-35001 Marburg Germany	State of Nationality DE	State of Residence DE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned	
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned	
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Carlos Roy Telephone No.: (41-22) 338.83.38
---	--

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 14 October 1997 (14.10.97)	
International application No. PCT/EP96/03199	Applicant's or agent's file reference 96927558.5
International filing date (day/month/year) 19 July 1996 (19.07.96)	Priority date (day/month/year)
Applicant FLECKENSTEIN, Bernhard et al	

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

25 September 1997 (25.09.97)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Eugénia Santos Telephone No.: (41-22) 338.83.38
---	--

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing:

29 January 1998 (29.01.98)

International application No.:

PCT/EP96/03199

Applicant's or agent's file reference:

96927558.5

International filing date:

19 July 1996 (19.07.96)

Priority date:

Applicant:

FLECKENSTEIN, Bernhard et al

1. The designated Office is hereby notified of its election made:



in the demand filed with the International preliminary Examining Authority on:

25 September 1997 (25.09.97)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was



was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer:

J. Zahra

Telephone No.: (41-22) 338.83.38